Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Incyte < Previous 1 2 3 4 Next > Incyte to Report Third Quarter Financial Results October 10, 2023 From Incyte Via Business Wire Tickers INCY Incyte to Present Multiple Studies from Dermatology Portfolio at 2023 European Academy of Dermatology and Venereology (EADV) Congress September 29, 2023 From Incyte Via Business Wire Tickers INCY Incyte to Present at Upcoming Investor Conferences August 22, 2023 From Incyte Via Business Wire Tickers INCY Replimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Patients with Cutaneous Squamous Cell Carcinoma July 31, 2023 From Incyte Via Business Wire Tickers INCY REPL Incyte Announces Positive Topline Results from Phase 3 Trial Evaluating Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis July 11, 2023 From Incyte Via Business Wire Tickers INCY Incyte to Report Second Quarter Financial Results July 11, 2023 From Incyte Via Business Wire Tickers INCY Data from Across Incyte’s Oncology Portfolio Accepted for Presentation at the 2023 ASCO Annual Meeting and EHA2023 Hybrid Congress May 25, 2023 From Incyte Via Business Wire Tickers INCY Incyte to Present at Upcoming Investor Conferences May 23, 2023 From Incyte Via Business Wire Tickers INCY Incyte Strengthens Research & Development Efforts Appointing Pablo J. Cagnoni, M.D. to New Leadership Role May 08, 2023 From Incyte Via Business Wire Tickers INCY Incyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical Programs May 02, 2023 From Incyte Via Business Wire Tickers INCY Incyte Announces Results from SCRATCH-AD Trial Demonstrating Substantial and Rapid Itch Reduction in Patients with Mild-Moderate Atopic Dermatitis Treated with Opzelura® (ruxolitinib) Cream May 01, 2023 From Incyte Via Business Wire Tickers INCY Incyte Announces European Commission Approval of Opzelura® (ruxolitinib) Cream for the Treatment of Non-Segmental Vitiligo with Facial Involvement in Adults and Adolescents April 20, 2023 From Incyte Via Business Wire Tickers INCY Incyte to Present at Upcoming Investor Conferences April 18, 2023 From Incyte Via Business Wire Tickers INCY Incyte to Report First Quarter Financial Results April 11, 2023 From Incyte Via Business Wire Tickers INCY Incyte Announces Japanese Approval of Pemazyre® (pemigatinib) for the Treatment of Patients with Myeloid/Lymphoid Neoplasms (MLNs) March 27, 2023 From Incyte Via Business Wire Tickers INCY Incyte Provides Regulatory Update on Ruxolitinib Extended-Release Tablets March 23, 2023 From Incyte Via Business Wire Tickers INCY Incyte Announces FDA Approval of Zynyz™ (retifanlimab-dlwr) for the Treatment of Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma (MCC) March 22, 2023 From Incyte Via Business Wire Tickers INCY Multiple Abstracts from Incyte’s Growing Dermatology Portfolio Featured at American Academy of Dermatology (AAD) Annual Meeting March 06, 2023 From Incyte Via Business Wire Tickers INCY Incyte Provides Update on Interim Analysis of Phase 3 LIMBER-304 Study of Parsaclisib and Ruxolitinib in Patients with Myelofibrosis March 03, 2023 From Incyte Via Business Wire Tickers INCY Incyte to Present at Upcoming Investor Conference February 16, 2023 From Incyte Via Business Wire Tickers INCY Incyte Announces 52-Week Results from Phase 2 Study Evaluating Povorcitinib (INCB54707) in Patients with Hidradenitis Suppurativa February 10, 2023 From Incyte Via Business Wire Tickers INCY Incyte Reports 2022 Fourth Quarter and Year-end Financial Results, Provides 2023 Financial Guidance and Updates on Key Clinical Programs February 07, 2023 From Incyte Via Business Wire Tickers INCY Incyte to Present at Upcoming Investor Conference January 24, 2023 From Incyte Via Business Wire Tickers INCY Incyte to Report Fourth Quarter and Year-End 2022 Financial Results January 17, 2023 From Incyte Via Business Wire Tickers INCY Incyte to Present at Upcoming Investor Conferences December 15, 2022 From Incyte Via Business Wire Tickers INCY Incyte’s Novel Mutant CALR Antibody Unveiled at ASH 2022 Plenary Scientific Session December 11, 2022 From Incyte Via Business Wire Tickers INCY Incyte Announces Data from Two LIMBER Studies Evaluating Combination Treatments in Patients with Myelofibrosis (MF) Presented at ASH 2022 December 10, 2022 From Incyte Via Business Wire Tickers INCY Incyte and CMS Announce Collaboration and License Agreement for Ruxolitinib Cream in Greater China and Southeast Asia December 02, 2022 From Incyte Via Business Wire Tickers INCY Incyte to Present at Upcoming Investor Conferences November 17, 2022 From Incyte Via Business Wire Tickers INCY Data From Incyte’s Oncology Portfolio to Be Presented at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting November 07, 2022 From Incyte Via Business Wire Tickers INCY < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.